|
To date, ovarian cancer (RV) remains a very significant problem in oncogynecology and is in fourth place in the structure of malignant tumors in women. Over the past decade, an increase in the incidence rate and detection rate with a slight decrease in mortality from this disease has been noted in the world [1, 2].
Moreover, the problem in the Russian Federation, as well as throughout the world, is far from being resolved. According to official statistics, in 2018, 3762218 patients with neoplastic diseases were registered in territorial oncological institutions of our country, which amounted to 2.6% of the total population of the country. Over the past 10 years, the number of oncological diseases in the Russian Federation has grown by 30.3%. Due to the late diagnosis, mainly due to women with its 3rd and 4th stage, every fifth patient with OW (22%) after diagnosis is living less than a year. In the Khanty-Mansi Autonomous Okrug, despite the younger population, there has also been an increase in cancer. At the same time, the mortality rate during the first year from neoplastic ovarian processes increased and amounted to 26.2% in 2018. When calculating the prognostic index ROMA (risk of malignancy algorithm) in patients with ovarian cancer, the indicator exceeded the upper range at the age of premenopause by 6 times, postmenopause – by 2.4 times. Only in patients with malignant ovarian tumors, regardless of age, the sensitivity of the ROMA index in the study groups was 100%, specificity-93.3% and 100%, prognosticality of diagnosis by the ROMA index-93.8% and 100%, absence of disease-100%, diagnostic efficiency of tumor detection-96.7% and 100% (high). The ROMA index was also the leading factor in detecting borderline ovarian tumors in pre-menopausal patients-OR 28 CI 95% (2.82-277.972).
Keywords:benign, borderline ovarian tumors, ovarian cancer, tumor markers, menopause, ROMA prognostic index.
|